B cell depletion is an effective therapy for a number of T cell-mediated autoimmune diseases, suggesting that B cells may contribute to autoimmunity 1-4 . However, subsequent studies showed that the efficacy of the CD20-specific antibody rituximab in some autoimmune diseases may be due in part to the expansion of a rare regulatory B cell population with greater resistance to CD20-specific antibodies 5, 6 . The B cellmediated suppression of autoimmunity is independent of autoantibody production and is due to secretion of the anti-inflammatory cytokine IL-10 (ref. 7). IL-10-producing B reg cells are rare, representing 1-2% of spleen B220 + cells in mice 8 , lack specific markers and have a pivotal role in maintaining immunological tolerance and restraining excessive inflammation in autoinflammatory diseases 9 . However, increased numbers of B reg cells can prevent sterilizing immunity to pathogens and inhibit immune responses to infectious agents by impairing optimal T cell responses 9 . Tumor-induced B reg cells are recruited to and expand in tumors and constitute an important mechanism used by tumor cells to evade protective immunity and support metastatic growth [10] [11] [12] .
B cell depletion is an effective therapy for a number of T cell-mediated autoimmune diseases, suggesting that B cells may contribute to autoimmunity [1] [2] [3] [4] . However, subsequent studies showed that the efficacy of the CD20-specific antibody rituximab in some autoimmune diseases may be due in part to the expansion of a rare regulatory B cell population with greater resistance to CD20-specific antibodies 5, 6 . The B cellmediated suppression of autoimmunity is independent of autoantibody production and is due to secretion of the anti-inflammatory cytokine IL-10 (ref. 7) . IL-10-producing B reg cells are rare, representing 1-2% of spleen B220 + cells in mice 8 , lack specific markers and have a pivotal role in maintaining immunological tolerance and restraining excessive inflammation in autoinflammatory diseases 9 . However, increased numbers of B reg cells can prevent sterilizing immunity to pathogens and inhibit immune responses to infectious agents by impairing optimal T cell responses 9 . Tumor-induced B reg cells are recruited to and expand in tumors and constitute an important mechanism used by tumor cells to evade protective immunity and support metastatic growth [10] [11] [12] .
Specific factors and mechanisms that induce or regulate B reg cells in vivo have recently been explored. IL-21-and CD40-dependent cognate interactions with T cells induce B reg cells that suppress experimental autoimmune encephalomyelitis 13, 14 . Similarly, a granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-15 fusokine induced B reg cells that suppressed experimental autoimmune encephalomyelitis, suggesting involvement of cytokines in the development or expansion of B reg cells 15 . Recent studies have shown that IL-35 can induce T reg cells 16, 17 . IL-35 is the newest member of the IL-12 family of heterodimeric cytokines 16, 18 and is comprised of Ebi3, a b chain subunit encoded by the Epstein-Barr virus (EBV)-induced gene 3 (IL27B), and the IL-12p35 a subunit encoded by IL12A 16, 19, 20 . IL-35 is produced by natural T reg (nT reg ) cells and contributes to their suppressive activities 16 . However, it is not clear whether other lymphoid cell types also produce IL-35, and its in vivo functions are not known because native IL-35 is not available. Given the close relationship between B and T cells, we speculated that IL-35 might also have a role in inducing B reg cells in vivo.
In rIL-35 inhibited the proliferation of primary mouse B cells (Fig. 1e) and induced the generation and expansion of IL-10-producing B cells [22] [23] [24] (herein referred to as B reg cells) (Fig. 1f,g ). rIL-35 also inhibited proliferation of the mouse B cell line WEHI-279 in a dose-dependent manner (Fig. 1h) , excluding the possibility that the suppressive effects might have derived from contaminating cells in our primary B cell preparation. IL-10 production by WEHI-279 cells was increased by rIL-35 ( Fig. 1i) , indicating that rIL-35 mediates their conversion into B reg cells. It is notable that p35 and Ebi3 inhibited lymphocyte proliferation but had a marginal effect on IL-10 production by B cells (Fig. 1f) or T cells (Supplementary Fig. 2b,c) , suggesting that the induction of B reg cells was mediated mainly by rIL-35. Coculture of purified rIL-35-induced B reg cells with freshly isolated CD19 + B cells suppressed B cell proliferation (Fig. 1j) , suggesting that rIL-35-induced B reg cells exhibit suppressive activity. Blockade of IL-10 using an IL-10-specific antibody abrogated the inhibitory effect of rIL-35 ( Supplementary Fig. 2d ). rIL-35 also suppressed T cell proliferation in coculture experiments by inducing T reg cells (Supplementary Fig. 2e,f) . We confirmed the specific activity of rIL-35 using commercially available antibodies specific to p35 or Ebi3, which abrogated the growth-inhibitory effect of rIL-35 on B cells and the capacity of rIL-35 to induce the conversion of B cells into B reg cells ( Supplementary Fig. 2g-i ).
IL-35 induces an IL-35-producing B reg cell population IL-35 induces an IL-35-producing T reg cell population called iTR35 cells that suppresses inflammation 17 . We therefore examined whether rIL-35 could induce IL-35-producing B cells. Lipopolysaccharide
RESULTS

IL-35 induces IL-10-producing B reg cells
To study the potential regulatory role of IL-35 in autoimmune diseases and examine whether it can be used to treat uveitis, we genetically engineered and produced mouse IL-35 in insect cells (Fig. 1a) . Details of the production and purification of mouse rIL-35 are presented (Online Methods and Supplementary Fig. 1 ). Single-chain Ebi3 or p35 migrated as a 33-kDa monomeric protein on denaturing SDS gels, whereas rIL-35 migrated as a ~67-kDa heterodimeric protein on native, nondenaturing gel (Fig. 1b) . We further purified rIL-35 using two cycles of fast protein liquid chromatography (FPLC) (Supplementary Fig. 1a,b) and characterized it by SDS-PAGE (Supplementary Fig. 1c) . We obtained accurate mass determination by sedimentation equilibrium analysis ( Supplementary Fig. 1d,e) . Western blotting and coimmunoprecipitation analyses using antibodies to Flag and V5 revealed a specific association of Ebi3 with p35 as a stable p35:Ebi3 heterodimeric complex (Fig. 1c) , which is consistent with a previous study 19 . As a control for the functional studies we used supernatant from insect cells transfected with the empty vector, pMIB (Fig. 1a) , and we refer to the dialyzed, filtered supernatant herein as pMIB. Western blot analysis established that pMIB does not exhibit immunoreactivity to p35, Ebi3, Flag or the V5 epitope (Fig. 1c) . Evidence that rIL-35 is a heterodimer of p35 and Ebi3 is based on the dual reactivity of antibodies to p35-and Ebi3-specific monoclonal antibodies with rIL-35 ( Fig. 1d) . In line with a previous report 16 , we demonstrated that the heterodimeric protein is biologically active by showing that rIL-35 suppressed T cell proliferation directly (Supplementary Fig. 2a Western blot IP and western blot Results represent at least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (Student's t test (two tailed)). Error bars (e-j), s.e.m.
from the whole spleen was 42.68% in LPS-injected mice compared to 29.78% in mice injected with rIL-35 alone, suggesting that rIL-35 inhibited the expansion of B220 hi cells (Fig. 2f) . Suppression of the B220 hi cells was accompanied by the appearance of a prominent population of CD5 + B220 lo B cells in mice treated with rIL-35 that was not present in mice treated with LPS alone (Fig. 2f) . Analysis of the B220 lo CD5 + B cells revealed that rIL-35 preferentially induced expansion of CD19 + CD5 + B220 lo B reg cells (Fig. 2g,h ). Fig. 3 ).
More than 7% of the rIL-35-induced B reg cells expressed cell-surface CD5, and >17% of these cells were Tim-1 + . However, less than 1% of the rIL-35-induced B reg cells expressed Foxp3 (Fig. 2e) .
We examined the effects of rIL (B220 + IL-10 + ) cells in the spleen (Fig. 3c) (Fig. 3a) .
In contrast, rIL-35-treated mice had trace or very mild EAU with limited pathology, as indicated by significantly lower EAU scores (Fig. 3a) . IL-35-treated mice with EAU had a reduced frequency of T H 17 (CD4 + IL-17 + ) and T H 1 (CD4 + interferon-g (IFN-g) + ) cells in the draining lymph node (LN) (Fig. 3b) and an increased frequency of B reg
IRBP immunized mice
Normal fundus Untreated pMIB treated rIL-35 treated ( Fig. 3g) Other results represent at least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. EAU scores were analyzed by nonparametric Mann-Whitney U test (two tailed Results represent at least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (Student's t test (two tailed) (Fig. 4f,g ), suggesting that rIL-35-induced B reg cells immunization, and on day 4 after immunization, we intravenously injected the purified B reg cells or IL-10 -B cells (1× 10 6 per mouse) into the mice. Fundoscopy and histological analysis of the eyes 21 days after immunization revealed that the untreated mice or mice that received IL-10 -B cells developed full-blown EAU (Fig. 4b,c) . Mice treated with B reg cells had limited EAU pathology with very few cells in the vitreous and no evidence of retinal folds (a hallmark of severe EAU) as compared to untreated mice or those injected with IL-10 -B cells (Fig. 4b,c) . Approximately 31.1% of the B reg cells present in the spleens of the untreated mice with EAU were IL-35 + B reg cells, whereas ~64.4% of the B reg cells in the spleens of mice that received the IL-10 + B cells were IL-35 + B reg cells (Fig. 4d) The prefix "p" indicates phosphorylation. Data represent at least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (Student's t test (two tailed)). NS, not significant. Error bars (b-e), s.e.m.
B cell proliferation and IL-10 production (Fig. 6b,c) .
We confirmed the requirement of these receptors in IL-12Rb2-or IL-27Ra-deficient B cells, as rIL-35 could not inhibit proliferation of these cells (Fig. 6d) or induce expansion of IL-10 + B reg cells (Fig. 6e) . Moreover, reciprocal coimmunoprecipitation analysis confirmed that IL-12Rb2 and IL-27Ra are expressed and interact in IL-35-stimulated B cells (Fig. 6f) . Generation of IL-35 + B reg cells required IL-35-induced signaling through the IL-12Rb2 or IL-27Ra chains (Fig. 6g) . Western blot analysis suggested that rIL-35 preferentially activates STAT1, STAT3 and STAT4 in T cells (Fig. 6h) , whereas in B cells, it signals primarily through STAT1 and STAT3 but not STAT4 (Fig. 6i and Supplementary Fig. 4c,d) . Taken Fig. 5 ). This observation is reminiscent of recent findings that IL-27p28 and IL-12p40 could not activate STATs but suppressed T cell proliferation by inhibiting STAT1, STAT3 and STAT4 activation by IL-27, IL-6 and IL-12, respectively 33, 34 . Thus, factors that regulate the stability of the non-covalently linked IL-35 (p35 and Ebi3) heterodimer 32 and the ability of the individual subunits to inhibit STAT activation suggest an additional layer of complexity that may underlie the physiological regulation of IL-35. The finding that p35 and Ebi3 inhibit might inhibit EAU by inducing expansion of endogenous B reg and T reg cells while inhibiting pathogenic T H 17 and T H 1 cells in recipient mice. We also isolated human B cells by negative selection using CD43 microbeads and incubated them with human rIL-35 in medium containing 10 mg ml -1 LPS for 3 days. Compared to untreated cells, human recombinant IL-35 induced expansion of human B reg cells from 1.38% to 30% (Fig. 4h) and inhibited the proliferation of human B cells in response to phorbol 12-myristate 13-acetate (PMA) (Fig. 4i) .
B reg cells suppress uveitis through IL-35 signaling and IL-10 We induced EAU in p35 KO (Il12a -/-), IL-12Rb2 KO (Il12rb2 -/-) or IL-10 KO (Il10 -/-) mice and examined whether loss of IL-35 or its signaling component 28 would compromise generation of B reg cells and exacerbate uveitis. Compared to wild-type (WT) mice, IL-12Rb2 KO mice developed severe EAU (Fig. 5a) and had an increased proportion of T H 17 cells in draining LNs (Fig. 5b) . In response to rIL-35, B cells from IL-12Rb2 KO or IL-10 KO mice failed to convert into IL-10-producing B reg cells (Fig. 5c) and could not induce suppression of proliferation of uveitogenic T cells (Fig. 5d) . EAU disease scores in p35 KO mice were comparable to those in WT mice (Fig. 5a) ; it is not clear whether the modest effect of p35 deficiency stemmed from the fact that IL-12 (which utilizes the p35 subunit) is required for the induction and exacerbation of EAU 29 .
The use of p35 KO or IL-12Rb2 KO mice to examine the requirement of IL-35 for in vivo B reg cell generation or B reg or IL-35 + B reg cell-mediated EAU suppression is problematic because IL-12Rb2 KO and p35 KO mice also have defective IL-12 signaling. We therefore sorted B cells from WT, p35 KO, IL-12Rb2 KO or IL-10 KO mice with EAU, stimulated them ex vivo with rIL-35 and investigated whether they could suppress EAU induced by adoptive transfer of uveitogenic cells. Mice that received pMIB-treated B cells from WT mice or rIL-35-treated B cells from IL-12Rb2 KO or IL-10 KO mice developed EAU with scores that were significantly higher or equivalent to the pMIB B cells, whereas mice that received rIL-35-treated B cells from WT mice had attenuated EAU pathology (Fig. 5e) and a reduced proportion of T H 17 cells (Fig. 5f) . Although the BALB/c mouse strain is very resistant to EAU induction 30 , Ebi3 KO (Ebi3 -/-) mice on a BALB/c background developed EAU characterized by optic neuritis, papilledema, retinal vasculitis, hemorrhage and high EAU scores (Fig. 5g) , and compared to the frequency of B reg cells in the spleens of WT mice (2.49%), the frequency of B reg cells in Ebi3 KO spleens was 2.5-fold less (1.03%) (Fig. 5h) . Nonetheless, B reg cells are detectable in Ebi3 KO mice, albeit at very low frequency (1.03%), suggesting the existence of alternative pathways that induce B reg cell expansion 14, 15 . A requirement for B reg and IL-35 + B reg cells in the suppression of uveitis is underscored by the development of severe EAU in B cell-deficient mice (μMT, mice homozygous for the Ighm tm1Cgn targeted mutation) that have an intact T reg cell compartment. Whereas rIL-35 suppressed EAU in WT mice, rIL-35 treatment did not suppress uveitis in μMT mice (Fig. 5i) . Although the data indicate that B reg and IL-35 + B reg cells possess intrinsic immunosuppressive activities, they also suggest that there is a meaningful non-B cell, IL-35-driven suppressor response in vivo.
IL-35 signals through IL-12Rβ2 and IL-27Rα in B cells
To examine the role of each receptor subunit of the IL-12 family of cytokines on rIL-35-mediated suppression of B cell proliferation or IL-10 induction, we silenced Il12rb1, Il12rb2, gp130 or Il27ra using siRNA specific to each receptor subunit (Fig. 6a) . Silencing IL-12Rb1 or the gp130 subunit did not affect IL-35-mediated inhibition of B cell proliferation (Fig. 6b) or induction of IL-10 (Fig. 6c) . Furthermore, gp130-specific neutralizing antibodies did not block IL-35-induced inhibition of B cell proliferation (Supplementary Fig. 4a ) or suppress IL-35-induced production of IL-10 in B cells (Supplementary Fig. 4b ). In contrast, silencing of IL-12Rb2 and IL-27Ra completely inhibited the effects of IL-35 on lymphocyte proliferation but could not induce B reg or T reg cells suggests that p35 and Ebi3 have functions independent of IL-35 and may constitute a new class of therapeutic cytokines that can be used to modulate host defense and anti-tumor immunity without the danger of inducing B reg cells that prevent sterilizing immunity.
Uveitis comprises a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology that accounts for more than 10% of severe visual handicaps in the United States. Although steroids and other anti-inflammatory drugs are effective therapies, renal toxicity and other adverse effects preclude prolonged usage 35 
